Immunomedics Inc (IMMU): David M Goldenberg , CSO & Chairman of the BOD of Immunomedics Inc sold 353,010 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $3.91 per share for a total value of $1,369,266.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 14, 2015, Don C Stark (director) sold 5,100 shares at $3.15 per share price.On Jun 16, 2015, Cynthia L Goldenberg (President and CEO) sold 210,991 shares at $4.09 per share price.Also, On Jun 16, 2015, David M Goldenberg (CSO & Chairman of the BOD) sold 210,991 shares at $4.09 per share price.On Jun 15, 2015, Brian A Markison (director) sold 5,564 shares at $4.22 per share price.
Shares of Immunomedics (IMMU) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -0.51% at $3.88 with 24,19,451 shares getting traded. Post opening the session at $3.86, the shares hit an intraday low of $3.84 and an intraday high of $4.03 and the price vacillated in this range throughout the day. The company has a market cap of $368 M and the number of outstanding shares has been calculated to be 9,48,04,080 shares. The 52-week high of Immunomedics is $5.44 and the 52-week low is $1.5.
Company has been under the radar of several Street Analysts.Immunomedics is Upgraded by Jefferies to Buy. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on May 6, 2016.
Immunomedics Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form or conjugated with radioactive isotopes chemotherapeutics cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130) which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC) respectively. It has other product candidates that target solid tumors and hematologic malignancies as well as other diseases in clinical and pre-clinical development-stages.